• International Journal of Internet, Broadcasting and Communication
• /
• 제13권2호
• /
• pp.36-42
• /
• 2021

This study aims to examine whether there are some differences in the cost stickiness of R&D expenses of IT companies before and after the COVID-19 crisis. Before COVID-19, IT companies did not reduce R&D expenses even if sales decreased, resulting in cost stickiness. As a result, it appears that during the COVID-19, IT companies adjust R&D expenses in proportion to changes in sales. This is interpreted as a reduction in R&D investment, which takes a long time to create results, in case of a decrease in sales due to uncertainty in future management performance due to the COVID-19 pandemic. In other words, during the COVID-19 risk period, IT companies, like other companies, reduced R&D expenses as sales decreased, resulting in reduced cost stickiness. This study differs from existing literature in that it examines the impact of the COVID-19 pandemic on the R&D expenditure behavior of companies in the IT industry.

• 지식경영연구
• /
• 제15권4호
• /
• pp.1-14
• /
• 2014

This study investigates earnings management of IPO firms in knowledge-based-industry. we analyse the relation between earnings management and R&D expenses(Research and development expense)which is an important expenditure in knowledge based management. First, we found that the earnings management is the largest in the year when the firm is enrolled on the market. Second, the IPO firms have higher DA(discretionary accruals) than existing firms on the market and the size of R&D expenses is larger, too. Finally, in the IPO firms in knowledge-based-industry, the higher accounting receivable and R&D expenses are, the more happens earnings management. Our study shows that the IPO firms of knowledge-basedindustry have high R&D expenses which are core expenditure. Also, earnings management has happened frequently in the IPO firms.

• 한국산학기술학회논문지
• /
• 제20권11호
• /
• pp.487-493
• /
• 2019

본 연구는 제약기업대상 연구개발비 무형자산비중을 살펴보고, 무형자산화 비중이 기업 가치에 영향을 미치는지 코스닥제약기업 중심으로 살펴보았다. 연구대상은 2011년부터 2017년까지 코스닥에 상장된 연도별, 기업별 연구개발비 회계자료가 있는 제약기업 39개를 표본으로 종속변수로 토빈Q, 독립변수로 연구개발비 무형자산화 비중으로 설계하여 패널데이터모형으로 분석하였다. 결론은 코스닥제약기업은 연구개발비 무형자산화 비중이 토빈Q(기업가치)에 부정적인 영향을 미치는 것으로 나타났다. 연구개발비 무형자산비중이 클수록 코스닥 제약기업에서는 기업가치가 낮아질 수 있다는 시사점을 제공한다. 즉, 코스닥 제약기업에서는 부채비율이 높을수록 투자규모를 늘리는 현상을 반영하기에 무형자산 비중이 커진다고 해서 기업가치가 증가하지 않는다는 것으로 설명할 수 있다. 본 연구는 기존 연구들은 연구개발비 총액을 기업 가치와 관련성을 규명한 연구들이 대부분인 반면, 연구개발비를 좀 더 세분화해서 '무형자산화 비중'만을 놓고, 코스닥 제약기업의 기업 가치에 영향을 미치는지 여부를 연구했다는 데 그 의의가 있다.

• 아태비즈니스연구
• /
• 제11권3호
• /
• pp.169-184
• /
• 2020

Purpose - This research is intended to analyze the current status and problems of tax benefits in the R&D sector and suggest ways to improve tax credit for research and manpower development expenses when various countries fiercely develop efforts to enhance national competitiveness through increased investment in R&D Design/methodology/approach - This study will examine the current status of the tax support system for domestic and foreign R&D, and suggest improvement measures to expand research and development activities in the future. Findings - First, a plan may be considered to abolish and perpetuate the sunset deadline for tax credit for research and manpower development expenses as in the case of the United States and Japan. This perpetuation can be a proactive measure to actively support long-term R & D investment in companies facing economic decisions under uncertainty. Second, it should be revised to raise the tax credit rate of large corporations, which are shrinking every year, compared to SMEs, so that both large corporations and SMEs can improve their international competitiveness and secure excellent technologies through R & D. Finally, the target technologies for each new growth engine and source technology should be expanded to various fields, including national cybersecurity enhancement technology, aviation engine technology, carbon emission and global cooling technologies, which are areas of interest in major overseas R&D countries, to help active R&D and investment in these areas. Research implications or Originality - This study can find a contribution in comparing and analyzing the national R&D tax support system and presenting improvement measures at a time when the benefits of tax credit for research and manpower development expenses of large companies are decreasing due to frequent tax law revisions and the government's factors of increasing tax revenues. In addition, recent research and development items and research technologies of foreign countries were analyzed by Nature's top 10 major science and technology issues, and advanced technologies that should be applied to target technology areas by new growth engine and source technology were specifically investigated and presented.

• 기술혁신연구
• /
• 제22권3호
• /
• pp.37-63
• /
• 2014

그 동안 정부는 기업부설 연구소의 인적 설립요건을 낮춤으로써 연구원수를 확대하고 중소기업에 대한 연구개발투자 확대를 통하여 중소기업의 연구개발활동과 투자를 유인해 온 바, 본 연구에서는 과연 그동안 정부의 정책이 중소기업의 연구개발활동에 어떤 효과가 있었는지를 대기업과의 비교를 통하여 실증적으로 분석하고자 한다. 이를 위해 특정 산업이나 정부 R&D 프로그램에 국한하지 않고, 18,272개에 달하는 기업 패널 데이터를 이용하여 정부 연구개발 직접투자의 효과를 분석했다. 분석결과, 그 동안의 정부 연구개발 직접투자로 중소기업은 연구원수가, 대기업은 매출액과 자체연구개발비가 증가되는 효과가 나타났으며, 통계적으로 유의하지는 않았지만 정부의 연구개발 직접지원이 오히려 중소기업의 자체연구개발비를 감소시키는 효과를 야기한 것으로 나타났다. 또한 중소기업과 대기업 모두 자체연구개발비를 증가시키는 가장 큰 요인은 기업의 매출액으로 나타났으며, 매출액을 증가시키는 요인은 정부 연구개발 직접투자 보다는 기업의 자체연구개발비로 나타났다.

• Asian Journal of Innovation and Policy
• /
• 제7권3호
• /
• pp.625-645
• /
• 2018

This paper's objective is to draw a decision guideline to continue research and development (R&D) investments in biotech start-ups facing the "Valley of Death" syndrome - a long negative profit period during a financial crisis. The data include financial indices as Net income, Revenues, Total stockholders' equity, Cash & equivalents, and R&D expenses of 18 major biotech companies (nine in negative profit and nine positive, in FY2008) and 15 major pharmaceutical corporations as benchmarks both in FY2008 and in FY2016 derived from the US SEC Database, EDGAR. A first methodology dealing with real options analysis assumes Total stockholders' equity as a growth option. And a second methodology, Bayesian Markov chain Monte Carlo (MCMC) analysis, is applied to test the probability relationship between the Total stockholders' equity and the R&D expenses in these three groups. This study confirms that Total stockholders' equity can play the role of a call option to support continuing R&D investments even in negative profits.

• 보건행정학회지
• /
• 제25권2호
• /
• pp.97-106
• /
• 2015

Background & Methods: The purpose of this research is to estimate the efficiency of the pharmaceutical firms and the determinants of their efficiency. Stochastic frontier analysis(SFA) and panel study are applied to the data of 60 domestic pharmaceutical firms from 2006 to 2012. Results & Conclusion: First, the result of the stochastic frontier analysis shows that overall efficiency of the pharmaceutical firms is increasing as time goes by. However, if firms are classified by the scale, the larger firms show more efficiency and if classified by the degree of innovativeness, the innovative firms show more efficiency compared to the non-innovative firms. This evidences show that the scale and R&D investment have significant relationships with the efficiency of the pharmaceutical firms. Therefore, it is necessary to increase the national level of investment for the fundamental researches to vitalize R&D of the new drugs. Second, the result of estimation of the determinants of efficiency shows that the firms with larger sales promotion expenses and entertainment expenses have less efficiency compared to the other firms. This can be explained by the structural characteristics of the small generic pharmaceutical firms. Therefore, the government had better make the pharmaceutical firms to reduce sales promotion and entertainment expenses and increase R&D expenses by introducing systems such as global budgeting system on medicine or reference pricing system.

• 한국산학기술학회논문지
• /
• 제19권12호
• /
• pp.854-862
• /
• 2018

기초연구투자, 성장동력창출 등 미래 성장시장 개척을 위해, 2019년도 정부R&D 예산은 20조원을 돌파하게 되었다. 이처럼 연구개발 투자의 중요성은 높아지고 있으며, 효율적이고 투명한 사업비 집행을 위한 다양한 제도 또한 확대 시행중이다. 그러나 사업비 부정집행 등 연구비 유용행위는 지속적으로 발생되고 있는바, 이에 대해 강력한 제재조치수단인 제재부가금 부과제도가 본격 도입 시행되고 있다. 본 논고에서는 제재부가의 법적근거, 부처 간 법령 비교검토, 부과기준(부과율) 분석을 실시하였으며, 실무 활용에 본 연구의 목적이 있다. 또한 부처 부가금 부과기준의 일원화 개정이후 단일기준을 적용 시행함에 따라, 이에 부가금제도의 변천과정을 고찰하고, 최근 3년간 부과자료를 근거로 구간별 부과현황 등 정밀분석을 실시하였다. 데이터 분석결과 소액 유용행위에 집중 부과되고 있음을 도출하였으며, 이에 상응한 새로운 정책방안을 제시하였다.

• 아태비즈니스연구
• /
• 제14권4호
• /
• pp.175-189
• /
• 2023

Purpose - The purpose of this study was to examine the relationship between CEO name uncommonness and R&D intensity while focusing on CEO ownership and CEO tenure as moderators of the relationship. Design/methodology/approach - This study collected data from various American databases such as national data on given names from Social Security Administration, COMPUSTAT, and Execucomp. The sample of this study includes 2,494 (firm-year) observations from U.S. firms between 2005-2011. This study conducts Feasible Generalized Least Square (FGLS) regression analysis to test the hypotheses. Findings - First, we found CEO name uncommonness was positively related to R&D intensity. In other words, CEOs with unusual names prefer being distinctive by increasing R&D investments. Second, we examine the moderating roles of CEO characteristics (i.e., CEO ownership and tenure). The results show that CEO tenure strengthens the positive relationship between CEO name uncommonness and R&D intensity. Research implications or Originality - First, this study extends the CEO characteristics and R&D literature by investigating how CEO name uncommonness affects R&D intensity. In addition, our study also supports the intitutionalization of CEO power arguments by showing that CEOs with unusual names are more likely to pursue distinctive strategies when they have longer tenure. For practical implications, our results allow the investors to better predict corporate future R&D expenses. It suggests that ceteris paribus, CEOs with unusual names, vis-a-vis CEOs with common names, are more likely to increase R&D expenses.

• 기술혁신학회지
• /
• 제21권4호
• /
• pp.1345-1365
• /
• 2018

본 연구는 정부와 전문기관간에 위임-대리인관계가 대리인문제를 발생시키고 연구관리전문기관의 효율성에 영향을 미칠 수 있다는 가정 하에, 법적위탁이 아닌 계약에 의한 위탁사업은 사업수탁에 대한 불확실성과 외부영향에 의한 대리인 비용 발생으로 법적 위탁사업 보다 효율성이 낮을 것이라는 가설을 검증하고 사업별 효율성에 미치는 영향요인들을 분석하고자 한다. 이를 위해 정부와 전문기관간의 세부사업별 사업위탁방식(더미변수)과 사업관리비 비율간의 관계를 분석하기 위해 사업방식(Top-down/bottom-up), 사업규모(예산, 과제수), 기관운영경비 편성비중, 기관의 수권예산대비 출연금 비율 등을 통제변수로 사용하였다. 분석결과에 따르면, 사업관리 효율성과 정부와의 사업위임방식(법적위임)간의 양의 상관성이 확인되었으며, 전문기관의 안정성과 독립성을 반영할 수 있는 법적지위 및 예산 구조 관점에서의 시사점이 도출되었다. 본 연구의 정책적 함의로서, 전문기관의 사업관리 효율성을 높이기 위해서는 법적인 안정성과 예산의 안정성이 확보되어야 하고 이를 통해, 위임자-대리인 문제에서 발생하는 도덕적 해이나, 역선택을 회피할 수도 있다는 점을 시사한다.